Literature DB >> 17709915

Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.

Mahmut Ilker Yilmaz1, Mutlu Saglam, Alper Sonmez, Kayser Caglar, Erdinc Cakir, Yasemin Kurt, Tayfun Eyileten, Mustafa Tasar, Cengizhan Acikel, Yusuf Oguz, Abdulgaffar Vural, Mujdat Yenicesu.   

Abstract

BACKGROUND: The aim of this study was to find out whether the beneficial effects of the renin-angiotensin-aldosterone system (RAS) blockage in chronic kidney disease (CKD) has any relation with the alteration of asymmetric dimethylarginine (ADMA) levels.
METHODS: Sixty-six nondiabetic patients with CKD and proteinuria and 36 healthy subjects were enrolled. Patients were treated with either ramipril 5 mg daily or valsartan 160 mg daily for 3 months. Proteinuria, ADMA, symmetric dimethyl arginine (SDMA), flow-mediated dilatation (FMD) and HOMA index measurements were performed both before and after the treatment.
RESULTS: ADMA, SDMA, hsCRP levels, HOMA index and proteinuria of patients were significantly higher (p < 0.001 for all) and FMD, L-arginine and L-arginine/ADMA ratio in CKD were significantly lower than controls. According to the multiple regression analysis, proteinuria levels were independently related to ADMA and SDMA levels.
CONCLUSION: Both drugs were equally effective in reducing elevated ADMA levels and improving endothelial dysfunction in CKD patients. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709915     DOI: 10.1159/000107410

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  8 in total

1.  Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.

Authors:  Mahmut Ilker Yilmaz; Jonas Axelsson; Alper Sonmez; Juan Jesus Carrero; Mutlu Saglam; Tayfun Eyileten; Kayser Caglar; Alper Kirkpantur; Turgay Celik; Yusuf Oguz; Abdulgaffar Vural; Mujdat Yenicesu; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

Review 2.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

3.  Losartan inhibits monocytic adhesion induced by ADMA via downregulation of chemokine receptors in monocytes.

Authors:  Mei-Fang Chen; Yuan-Jian Li; Tian-Lun Yang; Bin Lou; Xiu-Mei Xie
Journal:  Eur J Clin Pharmacol       Date:  2009-01-22       Impact factor: 2.953

4.  Determinants of hemodialysis-induced segmental wall motion abnormalities.

Authors:  Ruth F Dubin; Alexis L Beatty; John R Teerlink; Nelson B Schiller; Ann F Bolger; Dean Alokozai; Carmen A Peralta; Kirsten L Johansen
Journal:  Hemodial Int       Date:  2013-11-14       Impact factor: 1.812

5.  Peripheral vascular dysfunction in chronic kidney disease.

Authors:  Christopher R Martens; David G Edwards
Journal:  Cardiol Res Pract       Date:  2011-05-24       Impact factor: 1.866

6.  Modeling Disease Progression: Angiotensin II Indirectly Inhibits Nitric Oxide Production via ADMA Accumulation in Spontaneously Hypertensive Rats.

Authors:  Haidong Wang; Hao Jiang; Haochen Liu; Xue Zhang; Guimei Ran; Hua He; Xiaoquan Liu
Journal:  Front Physiol       Date:  2016-11-17       Impact factor: 4.566

7.  Assessment of subclinical atherosclerosis and endothelial dysfunction in chronic kidney disease by measurement of carotid intima media thickness and flow-mediated vasodilatation in North Indian population.

Authors:  Munna Lal Patel; Rekha Sachan; Gaurav Prakash Singh; S C Chaudhary; K K Gupta; Virendra Atam; Anit Parihar
Journal:  J Family Med Prim Care       Date:  2019-04

8.  Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury.

Authors:  Yosuke Nakayama; Seiji Ueda; Sho-ichi Yamagishi; Nana Obara; Kensei Taguchi; Ryotaro Ando; Yusuke Kaida; Ryuji Iwatani; Kumiko Kaifu; Miyuki Yokoro; Maki Toyonaga; Takuo Kusumoto; Kei Fukami; Seiya Okuda
Journal:  Kidney Int       Date:  2013-10-09       Impact factor: 10.612

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.